INBX
Inhibrx Biosciences, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$71.78Close
$1.0BMarket cap
$58.39 – $141.8452-week range
Nov 13, 2026Next report
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 18 · weaker than 82% of stocks over 12 months
- Far from its high 49% below its 52-week high
- Distribution down-day volume 1.9× up-day volume over 50 sessions
- Results soon Nov 13, 2026, in 12 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
49%
1wk
down 23.1%
price change
1mo
down 28.3%
price change
12-month return
down 9%
market up 11% ·
its own down 18%
F-score
—
— Not assessed
Altman Z
-0.04
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
130.9×
price / book
Earnings yield
down 13.2%
EBIT / enterprise value
Cheaper than
4%
of the market · expensive
Revenue growth
up 550%
year on year
EPS growth
—
latest quarter
Sales growth
down 100%
latest quarter
ROE
down 198%
return on equity
Free cash margin
down 9987%
-$129.8M FCF
D/E
12.58
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-89% then +550%)
Trade setup
ATR%
10.5%
$7.51 a day · 2×ATR $56.76
RS
18 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
1.4×
vs 50-day average
Up/down volume
0.52
50 sessions
Implied move
—
no option chain · report Nov 13, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: fails
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported
Aug 13, 2026
Last shock
Oct 28, 2026-23% in one session3.8× volumeno filing matched-2% since
Financials
- Net -10773%
- Free cash -9987%
- Cash
- Long-term debt
| FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|
| Revenue | $1.8M | $200,000 | $1.3M |
| Operating income | -$219.2M | -$331.4M | -$135.0M |
| Net income | -$241.4M | $1.7B | -$140.1M |
| Net margin | -13409% | 843786% | -10773% |
| Earnings per share | -$20.48 | $112.62 | -$9.04 |
| Free cash flow | -$197.9M | -$197.0M | -$129.8M |
| Free cash margin | -10995% | -98503% | -9987% |
| Cash | $277.9M | $152.6M | $124.2M |
| Long-term debt | $207.0M | $0 | $100.6M |
| Shareholders' equity | $43.5M | $133.6M | $8.0M |
| Shares outstanding | 47.37m | 14.48m | 14.58m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 13, 2026 | Quarterly ↗ | Jun 30, 2026 | 44d |
| May 14, 2026 | Quarterly ↗ | Mar 31, 2026 | 44d |
| Mar 19, 2026 | Annual ↗ | Dec 31, 2025 | 78d |
| Nov 14, 2025 | Quarterly ↗ | Sep 30, 2025 | 45d |
| Aug 13, 2025 | Quarterly ↗ | Jun 30, 2025 | 44d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 17, 2025 | Annual ↗ | Dec 31, 2024 | 76d |
| Nov 14, 2024 | Quarterly ↗ | Sep 30, 2024 | 45d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 28, 2026 | Regulation FD ↗ |
| Sep 8, 2026 | Regulation FD · Other events ↗ |
| Aug 13, 2026 | Results ↗ |
| Jul 16, 2026 | Material agreement · New obligation · Unregistered share sale · Regulation FD ↗ |
| Jun 15, 2026 | Regulation FD · Other events ↗ |
| Jun 3, 2026 | Shareholder vote ↗ |
| May 14, 2026 | Results ↗ |
| May 11, 2026 | Regulation FD · Other events ↗ |
| Apr 21, 2026 | Regulation FD · Other events ↗ |
| Mar 19, 2026 | Results ↗ |
| Feb 23, 2026 | Regulation FD ↗ |
| Dec 16, 2025 | Regulation FD · Other events ↗ |